Bain Capital Life Sciences Fund, L.P.'s Form 4 filing
Rapid Micro Biosystems, Inc.RPID · filed May 22, 2026
- Accession no.
- 0001193125-26-237016
- Filed
- May 22, 2026, 4:30 PM ET
- Trade date
- May 20, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bain Capital Life Sciences Fund, L.P.CIK 0001687968 | 10% Owner |
| BCIP Life Sciences Associates, LPCIK 0001702921 | 10% Owner |
| Bain Capital Life Sciences Partners, LPCIK 0001703030 | 10% Owner |
| Bain Capital Life Sciences Investors, LLCCIK 0001703031 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2026 | Class A Common Stock | PPurchaseAcquired | +1,463,000 | –F1 | – | 1,463,000 | Indirect | |
| May 20, 2026 | Class A Common Stock | PPurchaseAcquired | +1,463,000 | –F1 | – | 1,463,000 | Indirect | |
| May 20, 2026 | Class A Common Stock | PPurchaseAcquired | +1,463,000 | –F1 | – | 1,463,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On May 20, 2026, BCLS I Investco, LP ("BCLS I Investco") purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.
Referenced by the price of 3 transactions in Table II.